title: Vesicular monoamine transport inhibitors. Novel action at calcium channels to prevent catecholamine secretion.
abstract: Vesicular monoamine transport (VMAT) inhibitors, such as reserpine and tetrabenazine, impair vesicular catecholamine storage in chromaffin cells and sympathetic neurons, thereby lowering blood pressure. Here we describe a novel action of VMAT inhibitors-blockade of L-type voltage-gated calcium channels-that may also influence catecholamine release from both PC12 rat pheochromocytoma cells and bovine adrenal chromaffin cells. When given alone, VMAT inhibitors acutely release catecholamines from chromaffin cells in a dose-dependent fashion. However, VMAT inhibitors block catecholamine secretion stimulated by either nicotinic cholinergic agonists or cell membrane depolarization, each of which rely on the opening of L-type channels; the inhibition was more potent after long-term exposure to VMAT inhibitors (IC50 < 100 nmol/L). Reserpine blocked nicotinic-stimulated catecholamine release from neurite-bearing PC12 cells. Reserpine also antagonized catecholamine release triggered by combined membrane depolarization and the dihydropyridine L-type channel agonist Bay K8644, and reserpine blocked cellular uptake of extracellular 45Ca2+ in response to nicotine. Taken together, these results indicate that VMAT inhibitors are also antagonists at L-type voltage-gated calcium channels. Classic L-type channel antagonists (verapamil or nifedipine) also exhibited the reciprocal actions; acutely, they released norepinephrine from chromaffin cells, and chronically, they depleted cellular catecholamine stores, albeit with inferior molar potency to reserpine (IC50 < 1 nmol/L). We conclude that VMAT inhibitors and L-type calcium channel antagonists exert reciprocal inhibitory actions on each other's more classic pharmacological targets. Furthermore, these novel actions are seen at concentrations of these compounds frequently taken to be specific in vitro and likely to occur during antihypertensive treatment in vivo.
authors.affiliation: Department of Medicine, University of California, San Diego 92161, USA.
authors.forename: M
authors.initials: M
authors.lastname: Mahata
authors.forename: S K
authors.initials: SK
authors.lastname: Mahata
authors.forename: R J
authors.initials: RJ
authors.lastname: Parmer
authors.forename: D T
authors.initials: DT
authors.lastname: O'Connor
mesh_terms: D000311:Adrenal Glands / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000494:pharmacology; D015220:Calcium Channels / Q000187:drug effects*; D002417:Cattle; D002838:Chromaffin System / Q000166:cytology / Q000378:metabolism; D008562:Membrane Glycoproteins / Q000037:antagonists & inhibitors*; D026901:Membrane Transport Proteins; D009479:Neuropeptides; D009638:Norepinephrine / Q000037:antagonists & inhibitors* / Q000378:metabolism; D016716:PC12 Cells; D051381:Rats; D012110:Reserpine / Q000494:pharmacology*; D013747:Tetrabenazine / Q000494:pharmacology*; D050492:Vesicular Biogenic Amine Transport Proteins
chemical_list: D002121:Calcium Channel Blockers; D015220:Calcium Channels; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009479:Neuropeptides; D050492:Vesicular Biogenic Amine Transport Proteins; D012110:Reserpine; D009638:Norepinephrine; D013747:Tetrabenazine